European quality available to millions

The product, including the API is produced in Hungary, Budapest, according to GMP standards. Each batch is subjected to a multi-stage quality control, and the bioavailability of the product has been confirmed by studies conducted in Russia and Canada. More than 250,000 European patients are already receiving anticoagulant therapy by Egis rivaroxaban.

The product is available in 4 doses: 2.5 mg, 10 mg, 15 mg, 20 mg, which allows the doctor to select the optimal option for each patient depending on their condition and medical indication[1]. Rivaroxaban by Egis does not contain lactose, which reduces the risk of side effects in patients with lactatum insufficience[1]. The large package (98 tablets) offers long-term treatment convenience, reduces the need for frequent replenishment and allows you to save on treatment up to 5 times compared to therapy with original product[2].

"Often the high cost of anticoagulation drugs becomes an insurmountable barrier for many patients, especially elderly people. They are forced to make difficult choices between life-saving treatment and daily needs. That is why Egis considers it an important priority to make modern therapy available for every patient. Rivaroxaban is not just a new drug in Egis  - it is a chance for a quality life for millions of patients who need constant anticoagulant therapy", - emphasizes Olga Dukhanova, General Director of EGIS-RUS LLC.

[1]Instruction leaflet for medical use of the medical product Xiltess® ЛП-№(004676)-(РГ-RU) от 20.02.2024.

[1] IQVIA Dec’24, Rivaroxaban INN, Retail, price,  Rub.